More than 90% of cases of renovascular disease (RVD) are caused by atherosclerosis; thus patients with this condition are at high risk for vascular events. We examined the association of statins with prognosis in patients with RVD.
Introduction
Atherosclerotic renovascular disease (RVD) is a highly prevalent vascular condition, particularly among the elderly, with nearly 7% of community dwelling persons 65 years or older demonstrating RVD on duplex sonography. 1 In addition, patients with RVD incur high rates of cardiovascular and renal events. In the recent Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial, 37% of participants suffered a major cardiovascular event and 15% suffered a major renal event over a median follow-up of 34 months. 2 Among elderly patients with RVD captured in US Medicare data, annual rates of stroke, acute coronary syndrome, heart failure, and death were 18, 30, 19 , and 17%, respectively. 3 Randomized trials in RVD have typically focused on the role of revascularization in the management of this condition; remarkably few trials have assessed the effects of medical therapy on prognosis. Because .90% of RVD is caused by atherosclerosis, most experts recommend statin therapy for affected patients, although no statin trial has been conducted in this setting. Patients with RVD are on an average sicker, older and more likely to have renal impairment than the typical participant recruited to a statin 'mega-trial'; RVD might therefore complicate the risk-benefit ratio of statins. Alternatively, since RVD is often a marker of diffuse multisystem atherosclerosis, affected patients might have more to gain from adding a statin to their regimen.
We conducted a retrospective, population-based cohort study to evaluate the association between statins and cardiorenal outcomes in a defined sample of patients with RVD. 4 Because nonadherence is common in statin users, we performed our analyses using time-dependent covariates to model statin exposure throughout follow-up. In a sensitivity analysis, we also matched statin users to controls using propensity-based matching, which accounts for the likelihood of being prescribed a statin according to measured baseline characteristics. Finally, because statins seem to exert beneficial effects across disparate vascular beds, we assessed a spectrum of major cardiac, cerebral, and renal events in the primary analysis, while also testing these outcomes separately in secondary analyses.
Methods Setting and data sources
We conducted our study in Ontario, Canada using linked health-care databases in accordance with a fully prespecified research protocol.
Ontario is Canada's most populous and ethnically diverse province with a total population of .13 million, of whom 1.8 million are older than 65. Elderly patients in Ontario have universal access to health-care services, including outpatient medical visits, hospital care, home care, and prescription drugs. The large databases that record this care have been used extensively in past research, contain little missing information and have been validated for a diverse range of cardiovascular and renal events. 5 -8 We used six health databases: the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD), which records all hospital admissions in the province, including detailed diagnostic and procedural information; the Ontario Health Insurance Plan (OHIP) Database, which records information on outpatient medical visits and testing; the National Ambulatory Care Reporting System Database, which records emergency department visits, dialysis, oncological care, and cardiac catheterization; the Canadian Institute for Health Information Same Day Surgery (CIHI-SDS) Database, which records information on 'same day' interventions and procedures; the Ontario Drug Benefit Database, which records all prescription medications dispensed to patients 65 years of age or older; and the Registered Persons Database, which collects vital statistics on all Ontario residents. The study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre and the Privacy Office of the Institute for Clinical Evaluative Sciences.
Sample and selection
We included consecutive patients older than 65 years with codes identifying 'renal artery stenosis' or RVD in the CIHI-DAD, CIHI-SDS, and OHIP databases from 1 July 1994 to 1 July 2007 (a span of 13 years). Using a similar code set, Murphy et al.
9 calculated a specificity of 96% and sensitivity of 80% for angiographically verified RVD in a five-state validation study. We focused on patients older than 65 years because such individuals receive universal prescription coverage, and prescriptions dispensed are recorded in the Ontario Drug Benefit database. Furthermore, these subjects are highly likely to have atherosclerotic RVD. We excluded patients with fibromuscular dysplasia (n ¼ 21), death within 120 days of cohort entry (n ¼ 672), invalid health card number (n ¼ 215), missing age or sex (n ¼ 1), non-residents of Ontario (n ¼ 320), nursing home placement (n ¼ 563), or end stage renal disease prior to cohort entry (n ¼ 598). The rationale for each of these exclusions is detailed in Appendix 1.
Exposure
We defined statin exposure as receipt of one or more prescriptions for a hydroxymethylglutaryl coA reductase inhibitor within 120 days following the first identifying code for RVD (hereafter labelled the 'index date'). Since initially untreated patients might start a statin after this window, and initially treated patients might discontinue statin therapy, we modelled ongoing statin exposure as a timedependent covariate to reduce dilution bias from these factors. On the basis of serial prescription refills, we deemed cessation to have occurred following the last drug claim (if any) in the treatment group, and deemed initiation to have occurred following the first drug claim (if any) in the control group. As described below, we replicated this analysis using the more traditional 'intention-to-treat' approach, in which ongoing statin treatment was not reclassified following the initial exposure assessment. 
Characteristics and comorbidities

Outcomes
The primary outcome was time to a major cardiorenal event comprising myocardial infarction, stroke, heart failure, acute renal failure, dialysis, and death. Myocardial infarction, stroke, heart failure, and acute renal failure required admission to hospital with a most responsible diagnosis of the condition in question; death and dialysis were defined using both outpatient and inpatient databases (Appendix 2 for specific coding). We examined the six components of the primary outcome separately in secondary analyses. Follow-up for each patient began on the index date and continued until the event in question, death (for the secondary analyses) or 31 March 2008 (whichever came first). The primary analysis used time-dependent statin exposure assessment.
Sensitivity analyses
We conducted several additional analyses to test the robustness of our findings. First, we repeated our primary analysis using an intention-to-treat framework, which did not categorize statin exposure as a time-dependent covariate. Captopril nephrography (%) 234 (14) 337 (14) 0.73
Data are mean + SD or n (%). High socioeconomic status was defined by quintiles 3, 4, and 5. Numeric health-care data were rounded to the nearest integer. CTA, computed tomographic angiography; MRA, magnetic resonance angiography.
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diabetes mellitus, chronic kidney disease, coronary artery disease, and previous renal artery revascularization. Third, to capture the full extent of incident cardiorenal events in RVD, we prespecified three additional outcomes: hospitalizations with a most responsible diagnosis of malignant hypertension, hospitalizations with a most responsible diagnosis of renal disease (i.e. 'any renal hospitalization'), and revascularization procedures (comprising cerebrovascular, coronary, and peripheral arterial interventions). The intent of this analysis was to test the association of statins with morbid events which might not be captured in the primary outcome and its components. Fourth, we repeated our primary analysis using a traditional propensity score matching algorithm, pairing statin-exposed patients and untreated controls by propensity score (+0.2 standard deviations), age (+1 year), and sex. Of note this analysis does not use a time-dependent statin exposure assessment covariate but rather characterizes exposure according to treatment at baseline. It is therefore inherently more conservative since it does not account for treatment uptake among controls or treatment cessation and erratic adherence among statin users. Finally, we replicated our primary analysis in patients who did not change treatment over time, specifically excluding treated patients who discontinued statin therapy even temporarily together with controls who initiated statin therapy during follow-up.
Statistical analysis
Sample size calculations suggested that 2627 patients were required to detect as statistically significant a relative risk reduction of 20% or more, based on equal numbers of treated patients and controls, and an overall primary event risk of 30% in the control group (a ¼ 0.05, b ¼ 0.10). 3 We assumed a median follow-up of 2.5 years and attrition of 10%; this is conservative as emigration is ,0.5% per year among older individuals in our region. Given that in actual fact controls were somewhat more numerous than treated patients, 2709 patients were actually required to exclude the same risk reduction. We used Cox proportional hazards regression to test the association of statins with outcomes and to compute hazard ratios (HR) with 95% confidence intervals (CI). Multivariable analyses were adjusted for demographic characteristics, cardiovascular risk factors, comorbidities, measures of health-care utilization, screening, and medications. A twotailed P-value of ,0.05 was considered statistically significant. We performed all statistical analyses using SAS version 9.1 (SAS Institute, Carey, NC, USA).
Results
Over the 13-year accrual interval, we studied 4040 patients with RVD ( Table 1) . Comorbidities were highly prevalent, including hypertension (89%), coronary artery disease (54%), peripheral artery disease (46%), heart failure (46%), and cerebrovascular disease (30%). Fewer than half of all patients received a statin at baseline (n ¼ 1682; 42%). Not surprisingly, cardiovascular risk factors and comorbidities were more common in the statin group than among controls including diabetes (33 vs. 25%), hypertension (91 vs. 87%), chronic kidney disease (63 vs. 57%), coronary artery disease (62 vs. 48%), and cerebrovascular disease (32 vs. 29%). Diagnostic methods in this cohort included renal artery ultrasound (41%), catheter renal angiography (25%), computed tomographic angiography (23%), captopril nephrography (14%), and magnetic resonance angiography (7%).
The sample provided a total of 12 489 patient-years of follow-up with a median of 3.3 years (interquartile range 1.4 -5.0 years). In the primary analysis, statins were associated with a substantially lower risk of cardiorenal events (unadjusted HR 0.51, 95% CI 0.47-0.57; P , 0.0001). The primary outcome occurred at a rate of 63 and 103 events per 100 patient years at risk in statin users and non-users, respectively. After adjusting for demographic characteristics, cardiovascular risk factors, comorbidities, measures of health-care utilization, screening, and concomitant medications, this protective association was materially unchanged (adjusted HR 0.51, 95% CI 0.46-0.57; Table 2 ). In fully adjusted models, statins were associated with reduced rates of stroke (HR 0.72, 95% CI 0.54-0.96), heart failure (HR 0.83, 95% CI 0.69 -0.99), dialysis (HR 0.66, 95% CI 0.52-0.86), and death (HR 0.27, 95% CI 0.24-0.31), with a trend towards fewer myocardial infarctions (HR 0.82, 95% CI 0.65-1.04, P ¼ 0.099). Statins were not associated with any protective association for acute renal failure (HR 0.89, 95% CI 0.63-1.27); however, the latter was the least frequent component of the primary endpoint and this analysis may have been underpowered. As with the primary analysis, results were largely consistent in unadjusted and adjusted models ( Table 3) We conducted an intention-to-treat analysis to test the robustness of these findings, as well as to further evaluate absolute risk differences. In the unadjusted analysis, statins continued to exert a positive effect on the primary outcome although the strength of the association was approximately halved (HR 0.75, 95% CI 0.69 -0.83). These results were consistent with the adjusted analysis (HR 0.77, 95% CI 0.69-0.85). Replicating our results in patients who did not cross over between treated and exposed groups over time yielded similar findings (unadjusted HR 0.85, 95% CI 0.75-0.97, P ¼ 0.014; adjusted HR 0.85, 95% CI 0.73-0.99, P ¼ 0.031). Specifically, of the initially statin-treated patients, 1077 patients temporarily or permanently discontinued therapy; of the initially untreated controls, 711 patients later initiated statins during follow-up. Defined as first occurrence of myocardial infarction, stroke, heart failure, acute renal failure, dialysis, or death. 
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Porcine unilateral RVD model Renoprotective effects: reduced renal fibrosis and remodelling; increased renal blood flow and glomerular filtration rate Zhu et al.
22
Porcine unilateral RVD model Cardioprotective effects: left ventricular hypertrophy prevented; myocardial perfusion increased; reduced microvascular remodelling Laina et al. 23 
Rodent bilateral RVD model
Renoprotective effects: improved glomerular filtration rate, free water clearance, and fractional sodium excretion Lavi et al. 24 Porcine unilateral RVD model Renoprotective effects: improved endothelial function, reduced renal oxidative stress, inflammation and fibrosis; attenuated endothelial progenitor cell apoptosis Human studies Khong et al.
29
Case report (n ¼ 1) Marked regression of renal artery stenosis over 3 years following institution of statin therapy (and despite continued heavy smoking) Basta et al. 28 Case report (n ¼ 1)
Marked regression of renal artery stenosis, including spontaneous remission of hypertension and renin levels Bates et al. Cohort study (n ¼ 447) Reduced restenosis after renal artery stenting as well as greater freedom from recurrent symptoms (hypertension and worsening renal failure) with statins; risk ratios not provided Silva et al. 
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We also found a consistently positive association between statins and prognosis across each of the predefined subgroups, in both unadjusted and adjusted analyses (Figure 1) . A borderline statistical interaction was present for patients with a history of renal artery revascularization (P ¼ 0.053), with a stronger effect in those who received revascularization (HR 0.40, 95% CI 0.34-0.48) than in those who did not (HR 0.60, 95% CI 0.53-0.69). Of the cohort, 1927 patients had a history of renal revascularization and incurred a total of 767 primary outcome events, whereas 2113 had no previous history of renal revascularization (in whom 1202 events transpired). Finally, statin treatment was associated with a lower risk of all renal hospitalizations (HR 0.69, 95% CI 0.55-0.87) and malignant hypertension hospitalizations (HR 0.18, 95% CI 0.05-0.60) but not vascular interventions (HR 1.08; 95% CI 0.91-1.27; Table 3 ). Time-to-event curves showed gradual and continual separation for the primary outcome ( Figure 2 ) and mortality (Figure 3) throughout the entirety of follow-up. Figure 1 Subgroup analyses for the primary outcome of major cardiorenal events. All analyses were adjusted for demographic characteristics, cardiovascular risk factors, comorbidities, measures of health-care utilization, screening, and medications. For each subgroup, the square represents the hazard ratio with horizontal lines representing the 95% confidence interval.
Discussion
We found that statins were associated with a significantly lower rate of cardiorenal events in older patients with RVD. This finding was consistent with reductions in secondary endpoints, was present whether renal artery revascularization was performed or not, and was observed in the intention-to-treat analysis and propensity-based algorithm. The size of the apparent benefit is in keeping with the Heart Protection Study, the largest randomized trial of statins performed to date (n ¼ 20 536), which reported a number needed to treat of 19 for major vascular events in patients with occlusive vascular disease or diabetes. Reductions in renal events in the present study are also in keeping with several large randomized trials. 15 -19 Relation to the previous literature Several animal and human studies have reported on the effects of statins in RVD ( Table 4) . In randomized animal models of RVD, statins reduced renal fibrosis, improved kidney function and blood flow, prevented left ventricular hypertrophy, and increased myocardial perfusion. 20 -24 Four previous cohort studies demonstrated findings similar to ours, although the largest sample size in these reports was only a fifth of the present study.
11,25 -27
The most likely explanation is decreased progression, and possible regression, of renal artery stenosis with improved blood pressure under treatment with statins (as has been observed in one renal angiography cohort and several case reports 28, 29 ). In addition, antiinflammatory, antithrombotic, and antioxidant effects of statins may account for these findings. Because our analytical models do not contain on-treatment cholesterol levels, we are unable to determine the precise mechanism of this relationship.
Limitations
The major limitation of our study is the non-randomized comparison of statin use with untreated controls. Indeed the overall observational design raises possibilities of selection bias and residual confounding. We adjusted for 74 variables in our analyses and, if anything, statin users appeared to have greater cardiorenal comorbidity at baseline than controls. This imbalance would be expected to bias the results against treatment, yet this was not observed in any of the analyses. Adjusting for year of diagnosis did not materially change the results, suggesting that the present findings are not due solely to secular change. However, several variables could not be adjusted for such as laboratory measures of renal function, cholesterol, and anatomic grade of stenosis. Our data also lack lifestyle measures, such as obesity, smoking, and exercise. Outcomes in the current study were not blindly adjudicated and were based on administrative data. The coding of certain outcomes-such as malignant hypertension-have been validated in other jurisdictions but not in Ontario.
For these reasons, only a large randomized trial can conclusively demonstrate that statins improve prognosis in this setting; however, such a trial is unlikely to be performed given the high prevalence of compelling indications for statins in patients with RVD. In addition, our results might not apply to excluded patients, such as individuals with end stage renal disease, patients younger than 65, or those who died within 4 months of RVD diagnosis.
We cannot know for certain why patients were screened for RVD, but we did ascertain very high frequencies of hypertension (89%), chronic kidney disease (60%), and heart failure (46%) in this cohort. The fact that RVD is being detected in health-care databases, in concert with sizeable event rates, would suggest that patients with symptomatic RVD were likely enroled.
There are several reasons why some patients with RVD in our cohort may not have received statins. Patients who did not receive statins were less likely to have coronary artery disease, diabetes mellitus, and cerebrovascular disease at baseline. Such patients had equivalent rates of ambulatory care visits to general practitioners (P ¼ 0.51) and internists (P ¼ .30). We believe that adherence to treatment was unlikely to be a bar to statin therapy because controls still received an average of ten different drugs in the 6 months prior to cohort accrual. In addition, time-dependent exposure adjusts for medication adherence and drug uptake in both groups. Therefore, initially untreated controls still had a chance to receive statins after 'time zero' of follow-up, and indeed we found a general increase in statin treatment over the course of the study.
Notwithstanding the above remarks, we found some evidence of under-treatment in our study, with many patients with concomitant extra-renal atherosclerotic vascular disease not receiving statin therapy. Results in patients with or without coronary artery disease were virtually identical as shown in our predefined subgroup analyses. The beginning of our accrual period predated the results of the major statin trials in coronary disease, cerebrovascular disease, and peripheral arterial disease, during which time lipoprotein targets and thresholds became ever more rigorous. By the end of our accrual interval, statin users were outnumbering controls by a ratio of 2 to 1.
Conclusions
These findings suggest an association between statins and cardiorenal prognosis in patients with RVD (in keeping with data from previous studies). 11 -27,29 Our study also underscores the high rates of morbidity and mortality in this condition; overall, 49% of patients suffered a primary event and 37% of patients died during a median follow-up of 3.3 years. Given these rates, which are consistent with the previous literature, patients with RVD require careful surveillance and diligent risk factor modification to prevent cardiorenal complications. 2, 3 While randomized data do not exist to guide the nature of medical therapy for this condition, our findings suggest that patients with RVD should potentially be considered for statin therapy.
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